Merck KGaA touts FDA 'breakthrough' status, blockbuster potential in bid to woo investors
Merck KGaA set out to woo investors today by burnishing its pipeline prospects and spotlighting its drug candidate in the long-running race to release a treatment for a particularly aggressive form of lung cancer — insisting that they have a blockbuster upside in adding new revenue over the next 3 years.
Merck KGaA has received FDA breakthrough therapy status for tepotinib, a treatment for MET exon 14 skipping-mutated non-small cell lung cancer (NSCLC), joining Novartis’ capmatinib and a Pfizer treatment (Xalkori) in MET NSCLC drugs with ‘breakthrough’ status.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.